All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q3 report for BRISTOL-MYERS SQUIBB on October 20, 2026, reporting $80,000 in lobbying income.

Lobbying for BRISTOL-MYERS SQUIBB · Biopharmaceutical Company

All filings by THE MCMANUS GROUP · Everything BRISTOL-MYERS SQUIBB has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails Issues related to CMS fixed-dose combination drugs for Initial Price Applicability Year 2029 (CMS-4215-P)

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program

Bills named in this filing 1

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.